"Viral Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
| Descriptor ID |
D014765
|
| MeSH Number(s) |
D20.215.894.899
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Viral Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Viral Vaccines".
This graph shows the total number of publications written about "Viral Vaccines" by people in this website by year, and whether "Viral Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Vaccines" by people in Profiles.
-
Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2025 Jan 01; 43(Pt 1):126479.
-
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27; 16(9).
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
-
Vaccine value profile for norovirus. Vaccine. 2023 11 03; 41 Suppl 2:S134-S152.
-
Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes (Basel). 2022 10 25; 13(11).
-
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 05; 9(5):e309-e322.
-
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med. 2022 03 28; 20(1):128.
-
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Cell Rep Med. 2022 Mar 15; 3(3):100535.
-
In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect. BMC Bioinformatics. 2021 Mar 26; 22(1):163.
-
COVID-19 vaccines and neglected pregnancy. Lancet. 2020 09 05; 396(10252):e22.